Swiss Pharma Nigeria Limited (SWIPHA) has commenced the recall of all batches of Polyfort Suspension in stock over negative trend.
Polyfort Suspension is used to treat heartburn, indigestion, hyperacidity, and flatulence.
The pharmaceutical company announced the recall of Polyfort Suspension in a letter dated 27th April 2023, signed by the company’s Quality Manager, Olanrewaju Balaja and the Superintendent Pharmacist/BDD, Abbas Sambo.
SWIPHA, in the letter titled ‘Recall Exercise for Ployfort Suspension’ and addressed to its distributors and customers said the recall was “on account of the result of ongoing stability study on batches LS222072, LS222073 and LS222074, showing a negative trend.”
The company in the letter wrote below:
“Kindly be informed that we are initiating an immediate recall for all batches of Polyfort Suspension in stock.
“This is on account of the result of ongoing stability study on batches LS222072, LS222073 and LS222074, showing a negative trend. We are currently carrying out further investigation on other batches.
“However, we are mandated to inform you within 24 to 48 hours. We are unable to wait for the outcome of this investigation, hence, the decision to recall all batches of Polyfort in your custody.
“Further sales of Polyfort Suspension in your custody should be stopped, and inventory segregated immediately. Also, contact customers to whom you sold Polyfort Suspension to return them back to you. All Polyfort stock (your stock and that of your customers) should be handed over to the Swipha medical or sales representatives assigned to you.
“We expect that all the packs of the concerned product are made ready for retrieval by the 5 of May 2023 and a corresponding credit note will be issued (covering your stock and that of your customer).
“The field force will inform you of developments as they evolve.”
